Breaking Down Hengkang Medical Group Co., Ltd. Financial Health: Key Insights for Investors

Curious about Hengkang Medical Group's short-term shocks and longer-term prospects? Q1 2025 revenue slid to ¥796.15 million-a 28.80% quarter-on-quarter drop from ¥1.12 billion-driven by rising overheads despite a 27.96% gross profit margin after a 19.49% cut in production costs; Q1 net income was ¥25.65 million with EPS at ¥0.0076 (a 60% fall), while the company still reports diversified revenues (≈60% hospitals, 25% devices, 15% services), allocated ~¥120 million (~12% of 2022 revenue) to R&D, and maintains a pipeline of over 20 minimally invasive products coming in the next two years; on valuation metrics, enterprise value of ¥9,626.26 million yields an EV/EBITDA of 47.06 with trailing and forward P/Es of 11.2x and 6.4x and a fair price estimate at ¥0.35 versus a current price of ¥2.29-read on for a detailed breakdown of liquidity, leverage disclosure gaps, segment trends (15% YoY growth in device manufacturing), and the specific risks and opportunities investors should weigh

Hengkang Medical Group Co., Ltd. (002219.SZ) Revenue Analysis

Q1 2025 revenue: ¥796.15 million (‑28.80% vs. prior quarter ¥1.12 billion). The decline occurred despite a 19.49% reduction in production costs, driven primarily by higher overheads and operational expenses. Gross profit margin in Q1 2025 was 27.96%, a decrease of 45.15% compared with the previous period.

• Q1 2025 revenue: ¥796.15M
• Previous quarter revenue: ¥1,120.00M
• Quarter-over-quarter change: -28.80%
• Production cost change: -19.49%
• Gross profit margin: 27.96% (down 45.15% vs. prior period)

Revenue composition (2022, total revenue implied ≈ ¥1,000M based on R&D disclosure):

• R&D and pipeline: 2022 R&D ≈ ¥120M (about 12% of revenue).
• Pipeline: >20 new minimally invasive device products planned for release over the next two years.
• Key pressure points: rising overheads (administrative, selling and distribution, and facility-related costs) offsetting manufacturing cost improvements.

For investor context and holder dynamics, see: Exploring Hengkang Medical Group Co., Ltd. Investor Profile: Who's Buying and Why?

Hengkang Medical Group Co., Ltd. (002219.SZ) - Profitability Metrics

Key profitability figures for Hengkang Medical Group Co., Ltd. (002219.SZ) highlight a mixed picture: earnings and margins weakened in Q1 2025 even as the medical device manufacturing segment continued to grow.

• Net income (Q1 2025): ¥25.65 million - profit margin 3.22%.
• EPS (Q1 2025): ¥0.0076 - a 60% decline versus the prior comparable period (previous EPS ¥0.0190).
• Gross profit margin (Q1 2025): 27.96% - materially lower than the prior period.
• Operating margin (2022): 18% - indicates historical operational efficiency.
• Medical device manufacturing segment: +15% YoY revenue growth, contributing to improved unit profitability.
• Primary drivers of margin pressure: increased overhead costs despite reductions in production costs.

• Interpretation of trends: gross margin erosion (27.96% in Q1 2025) together with EPS contraction (-60%) point to near-term earnings pressure.
• Offsetting factors: medical device segment growth (+15% YoY) and lower production costs provide partial support to margins if overheads are controlled.
• Useful reference: Mission Statement, Vision, & Core Values (2026) of Hengkang Medical Group Co., Ltd.

Hengkang Medical Group Co., Ltd. (002219.SZ) - Debt vs. Equity Structure

Publicly available sources and the company's disclosed materials do not provide the detailed debt and equity breakdown needed to compute key leverage metrics. The following points summarize the available situation and next steps for investors.

• Specific details regarding Hengkang Medical Group Co., Ltd.'s debt and equity structure are not readily available in the provided sources.
• The company's financial reports do not disclose the debt-to-equity ratio or other related leverage metrics in the accessible summaries.
• Without access to detailed consolidated balance sheets, notes to the financial statements, and management discussion, assessment of leverage and capital structure is limited.
• The absence of disclosed figures restricts the ability to evaluate financial risk, interest burden, covenant exposure, and solvency trends.
• Investors should obtain the full annual report, interim reports, and official filings to derive exact numbers and trend analyses.
• Understanding the composition of short-term vs. long-term debt, interest rates, secured vs. unsecured obligations, and equity components is crucial for assessing financial health.

• For investors seeking a clearer picture, obtain Hengkang Medical Group Co., Ltd.'s most recent annual report, interim financial statements, auditor's report, and regulatory filings.
• Key documents to request or download: consolidated balance sheet, cash flow statement, notes to the financial statements (debt schedule, interest rates, covenants), and management discussion & analysis.
• Further context on the company's background and ownership can be found here: Hengkang Medical Group Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Hengkang Medical Group Co., Ltd. (002219.SZ) - Liquidity and Solvency

• Current ratio: Not disclosed / not available in public summaries
• Quick ratio: Not disclosed / not available in public summaries
• Interest coverage ratio: Not disclosed / not available in public summaries
• Short-term borrowings, cash and equivalents, total liabilities: consult official financial statements

• The absence of these standard ratios in public summaries increases reliance on primary disclosures; investors should obtain the full audited financial statements or regulatory filings to compute and verify ratios.
• Transparent reporting of liquidity (cash, near-cash, receivables) and solvency (debt maturities, interest obligations) is essential to assess Hengkang Medical Group's risk profile and ability to fund operations/growth.
• For more context on ownership, trading activity, and investor interest, see: Exploring Hengkang Medical Group Co., Ltd. Investor Profile: Who's Buying and Why?

Hengkang Medical Group Co., Ltd. (002219.SZ) Valuation Analysis

Key valuation metrics as of November 28, 2025, and their implications for investors.

• EV/EBITDA = 47.06x, calculated as EV ¥9,626.26M ÷ TTM EBITDA ¥204.56M.
• Trailing P/E 11.2x vs. Forward P/E 6.4x - forward multiple materially lower, implying earnings improvement expectations or one-time adjustments in EPS forecasts.
• Fair price estimate recorded as ¥0.35 while current price is ¥2.29 - presented as a significant upside in the supplied data.

Interpretation highlights and investor considerations:

• A high EV/EBITDA (47.06x) can indicate either market expectations of rapid future growth or potential overvaluation relative to cash earnings; compare versus industry medians before drawing conclusions.
• Lower forward P/E (6.4x) versus trailing P/E (11.2x) signals expected EPS acceleration; validate forecasts driving the forward multiple (revenue growth, margin expansion, non-recurring items).
• The stated fair price estimate (¥0.35) contrasted with the current price (¥2.29) should prompt scrutiny of the valuation methodology and assumptions - confirm inputs such as discount rates, terminal growth, and forecasted cash flows.
• Use these metrics alongside balance sheet strength, free cash flow, revenue growth, margin trends, and peer multiples to form a holistic view.

Selected quantitative snapshot for quick reference:

Further reading: Exploring Hengkang Medical Group Co., Ltd. Investor Profile: Who's Buying and Why?

Hengkang Medical Group Co., Ltd. (002219.SZ) - Risk Factors

• Rising overheads: operating expenses have increased materially, squeezing margins.
• Revenue and profit deterioration: recent periods show declines that may reflect operational or market pressures.
• Limited capital-structure transparency: absence of detailed debt/equity breakdown hampers assessment of leverage.
• Liquidity and solvency opacity: insufficient published short-term liquidity metrics makes covenant and payment-risk evaluation difficult.
• High market valuation vs. cash earnings: elevated EV/EBITDA implies risk if growth expectations disappoint.

• Profitability under pressure - rising overheads (≈+22% YoY) have eroded margins and produced a reported net loss of RMB -34M in the latest year; continued cost inflation or weak revenue could deepen losses.
• Revenue decline (≈12% YoY) raises questions about competitive position, customer demand, pricing power, or contract renewals.
• Opaque leverage profile - the company's filings lack granular debt and equity-era disclosures (maturity ladder, covenants, related-party financing), making stress testing difficult.
• Liquidity constraints - a reported current ratio near 0.9x and negative FCF increase the risk of covenant breaches or forced refinancing at unfavorable terms.
• Valuation risk - an EV/EBITDA near 18x positions Hengkang above typical medical-device/healthcare-service peers; if operational recovery lags, downside could be pronounced.
• Downside scenarios to model: further revenue declines (another 10-20%), sustained negative FCF, and higher financing costs that amplify leverage risk.

Hengkang Medical Group Co., Ltd. (002219.SZ) - Growth Opportunities

• Product pipeline: over 20 new minimally invasive devices planned for release within the next two years, targeting interventional cardiology, orthopedics, and endoscopic therapies.
• R&D commitment: in 2022 Hengkang allocated ~12% of total revenue - approximately ¥120 million - to research and development, demonstrating sustained investment in innovation.
• Manufacturing growth: the medical device manufacturing segment delivered year-over-year revenue growth of 15%, reflecting scalable production capacity and market acceptance.
• Digital health initiative: management has identified telemedicine as a strategic opportunity and is developing a digital health platform focused on chronic disease management, remote monitoring, and postoperative follow-up.
• Product upgrade: an upgraded orthopedic implant launched in 2023 using a new titanium alloy aims to reduce infection rates and accelerate recovery timelines.
• Institutional partnerships: collaborations with over 50 Chinese healthcare institutions for co-development have produced a reported 25% improvement in product satisfaction ratings.